A trial fibrillation (AF) increases the risk of stroke, disability, dementia, and death, with a characteristic profile of more severe, disabling, and recurrent stroke compared with stroke without AF. [1] [2][3][4] With aging populations, the prevalence of AF is projected to increase ≥2-fold by 2050, accompanied by an increase in the frequency of AF-associated stroke. 5 Accurate health economic data are important to inform health policy decisions to respond to this societal increase in AF prevalence, such as population screening programs. Reliable data on the cost of stroke associated with AF (AF-stroke) are also essential for rigorous cost-effectiveness studies of new oral anticoagulant agents, which guide reimbursement decisions for healthcare providers internationally. [6] [7] [8] [9] Existing hospital-based studies have described high costs of stroke associated with AF. [10] [11] [12] [13] [14] [15] However, existing studies have been limited by the reporting of acute hospital costs only, or by the inclusion of selected AF-stroke subgroups, such as hospitalized patients, nonaphasic patients, those with first-ever stroke only, or 1-year survivors. No cost studies of AF-stroke have been performed in unselected patients, including costs of community healthcare and indirect costs associated with lost productivity, leading to substantial underestimation of the Background and Purpose-No economic data from population-based studies exist on acute or late hospital, community, and indirect costs of stroke associated with atrial fibrillation (AF-stroke). Such data are essential for policy development, service planning, and cost-effectiveness analysis of new therapeutic agents. Methods-In a population-based prospective study of incident and recurrent stroke treated in hospital and community settings, we investigated direct (healthcare related) and indirect costs for a 2-year period. Survival, disability, poststroke residence, and healthcare use were determined at 90 days, 1 year, and 2 years. Acute hospital cost was determined using a case-mix approach, and other costs using a bottom-up approach (2007 prices). Results-In 568 patients ascertained in 1 year (2006), the total estimated 2-year cost was $33.84 million. In the overall sample, AF-stroke accounted for 31% (177) of patients, but a higher proportion of costs (40.5% of total and 45% of nursing home costs). On a per-patient basis compared with non-AF-stroke, AF-stroke was associated with higher total (P<0.001) and acute hospital costs (P<0.001), and greater nursing home (P=0.001) and general practitioner (P<0.001) costs among 90-day survivors. After stratification by stroke severity in survivors, AF was associated with 2-fold increase in costs in patients with mild-moderate (National Institutes of Health Stroke Scale, 0-15) stroke (P<0.001) but not in severe stroke (National Institutes of Health Stroke Scale ≥16; P=0.7). Conclusions-In our population study, AF-stroke was associated with substantially higher total, acute hospital, nursing home, and general practitioner costs per patient. Targeted programs to identify AF and prevent AF-stroke may have significant economic benefits, in addition to health benefits. 
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total societal cost of AF-associated stroke. Population-based studies with late follow-up are needed, reporting direct and indirect costs in unselected hospital-and community-treated patients with first-ever and recurrent stroke events. We hypothesized that AF-associated stroke would be associated with higher early and late hospital, community, and indirect costs when compared with stroke without AF. We aimed to investigate the total cost of AF-associated stroke for a 2-year period in the North Dublin Population Stroke Study and to examine the influence of severity and age on AF-related stroke costs.
Methods
The North Dublin Population Stroke Study is a population-based prospective cohort study of stroke and transient ischemic attack (TIA) in 294 529 North Dublin city residents. 16 Ascertainment of stroke and TIA events was conducted in 2006, after rigorous gold-standard criteria for stroke incidence studies (Methods in the online-only Data Supplement). 17 Using hot and cold pursuit methods in multiple overlapping hospital and community sources, we identified incident and recurrent stroke and TIA events. We also used the Oxford Vascular Study (OXVASC) additional ascertainment sources (regular reviews of all referrals for brain and neurovascular imaging, assessment of all cases with definite or possible TIA, follow-up of all confirmed TIA cases for stroke occurrence). Independent validation studies in Dublin and OXVASC have suggested complete ascertainment using these techniques. 18 AF (known or new diagnosis) was defined consistent with current European Society of Cardiology guidelines 19 as known physiciandiagnosed AF preceding stroke onset, or new detection of persistent, permanent, or paroxysmal AF at the time of, or within 90 days of, the index stroke. The World Health Organization definition of stroke was used.
The source population was quantified from 2006 census data for North Dublin city. The total population was 294 529 individuals, comprising 7% of the Irish population. Ethics committee approval was obtained from participating hospitals and the Irish College of General Practitioners, and informed consent was obtained.
For this analysis, prespecified inclusion criteria were as follows: (1) new ischemic or hemorrhagic stroke (intracerebral hemorrhage or subarachnoid hemorrhage) within the study ascertainment period; (2) hospital-admitted or community-treated patients; (3) residence within North Dublin city, defined by the Irish District Electoral Division system reported in the national census. We excluded patients with TIA and those resident outside North Dublin city.
We calculated direct and indirect costs to reflect the societal economic burden of AF-associated stroke on hospitals, other health agencies, and individuals (Methods in the online-only Data Supplement). 20 Direct costs were defined as to those directly related to the provision of health care, such as hospital inpatient care for first-ever or recurrent stroke, drug prescription costs, general practitioner care, outpatient specialist consultations, and community healthcare services, such as home-based care assistance. Indirect cost was defined as the cost of loss of productivity because of stroke morbidity.
For hospital admission costs of the index stroke event and repeat hospital admissions during follow-up, overall total healthcare expenditure per diagnosis-related group was used to allocate cost per patient (top-down approach). For all other cost categories, unit costs for specific services were combined with treatment use rates (bottomup approach; Methods and Tables I to IV in the online-only Data Supplement). All costs were calculated on the basis of 2007 Euros (€1 equated to ≈$1.37 at 2007 average exchange rates). Summary estimates of per-patient costs are reported unless otherwise specified.
Statistical Analysis
Bivariate comparisons of proportions were calculated using χ 2 tests. Parametric comparisons of continuous variables were performed using t tests. Analysis of healthcare cost data is frequently complicated by skewed distributions with a large number of zero values. 21 Because our data had such a distribution, nonparametric comparisons of continuous variables were done using the median test, which requires no underlying assumptions about data distribution. Because the data did not sufficiently meet underlying assumptions for γ distribution multivariable modeling, we adopted a conservative approach and investigated the influence of stroke severity and age in stratified analyses. All statistical analyses were performed on Stata (version 12). Prespecified sensitivity analyses were performed on subgroups with ischemic stroke only and survivors at 90 days.
Results

Clinical Characteristics and Late Outcomes
In the 1-year ascertainment period, 568 patients with a qualifying event of new (first-ever or recurrent) stroke were identified (177 AF-stroke and 391 non-AF-stroke). Of these, 90.7% (515 patients) were treated acutely in hospital and 9.3% (53 patients) in the community. Stroke mechanisms were ischemic (458 patients; 80.6%), primary intracerebral hemorrhage (61 patients; 10.7%), subarachnoid hemorrhage (30 patients; 5.1%), and undetermined (19 patients; 3.7%). Clinical characteristics are described in the Follow-up was complete for 97.9% at 90 days (556/568) and 94.2% at 2 years (545/568). Early outcomes have been previously described. 1 Patients with AF-stroke had greater late disability and fatality compared with those without AF. At 2 years, good outcome (modified Rankin Scale score, 0-2) was observed in 25.7% of patients with AF compared with 47.4% of those without AF (P<0.0001). Case fatality at 2 years was 50.3% in patients with AF compared with 35.1% in those without AF (P=0.001). At 2 years, the odds ratio of disability or death (modified Rankin Scale, ≥3) associated with AF was 2.6 (95% confidence interval, 1.75-3.85).
Total and Acute Hospital Costs
The total direct and indirect costs in the entire cohort were $33.8 million by 2 years. Although AF accounted for 31% of the cohort, 40.5% of all costs were incurred by AF-stroke ($13.6 million). At an individual patient level at 2 years, total healthcare costs in AF-stroke were substantially greater than non-AF-stroke (Figure 1 ; median, $36 865 versus $18 691; P<0.001; Table V in the online-only Data Supplement). On bivariate analysis, female sex (P=0.054), poststroke (72 hours) National Institutes of Health Stroke Scale (ρ=0.14; P=0.002), and modified Rankin Scale (ρ=0.12; P=0.005) were also associated with total costs, but not age, recurrent stroke, hypertension, current smoking, diabetes mellitus, or coronary disease.
AF-stroke was associated with greater acute hospital length of stay and resource use ( Figure 1 ; Table V in the online-only Data Supplement). AF-stroke accounted for 38.5% of total acute inpatient costs ($6.1 of $15.9 million). Median acute inpatient hospital costs for AF-stroke were $15 025 compared with $11 196 for stroke without AF (P<0.001). Our results were unchanged when repeated in the ischemic stroke subgroup.
Community and Posthospital Costs
At 90 days, 71.8% (209/291) of surviving patients without AF were living at home compared with 60.8% (79/130) those with AF-stroke (P=0.03), whereas 16.9% (22/130) of those with AF-stroke were resident in nursing homes compared with 6.5% (19/291) of non-AF stroke (P=0.001). At 2 years, proportions resident in nursing homes were 18.7% (AF) and 9.5% (non-AF; P=0.001). AF-stroke accounted for 45.1% of all nursing home costs by 2 years ($4.37 of $9.7 million). Among patients surviving ≥90 days, AF-stroke was associated with greater total nursing home costs by 2 years (P=0.001; Table V in the online-only Data Supplement).
Patients with AF-stroke who were discharged home required greater input of community-based health services, such as home healthcare assistance for personal needs. Of the 79 surviving patients with AF-stroke living at home at 90 days, 50.6% (40/79) reported uptake of community health services compared with 40.2% (84/209) of non-AF patients (P=0.05). In patients surviving ≥90 days, the mean 2-year cost of community health services in patients with AF-stroke was $7875 compared with $5392 in those without AF (P=0.09). A greater proportion of AF patients discharged to home also required purchase of additional equipment (eg, hoist, electric bed, wheelchair) or home modifications to meet healthcare needs (38.0% versus 21.6%; P=0.03). However, equipment and home modification costs were not significantly greater in patients with AF.
In 90-day survivors with AF-stroke, the cost of general practitioner visits by 2 years was greater (P<0.001), and cost of hospital specialty clinics was less (P<0.001). No difference in total medication costs was observed (P=0.7; Table VI in the online-only Data Supplement).
Cost of Lost Productivity
Fewer patients with AF-stroke were in employment at stroke onset (4.1% versus 20.2%; P<0.001), but no significant difference was observed for greater lost-productivity costs (P=0.08).
Early Fatality, Severity, Age, and AF-Stroke Costs
Exploratory stratified analyses were performed to examine the relationships between AF, fatality, severity, age, and cost further. Case fatality at 90 days was 26.9% (47/175) in AF-stroke and 26.3% (100/381) in non-AF-stroke (P=0.9). Higher costs were observed in 90-day survivors compared with those who died (P<0.001; Figure 2 ).
In survivors, acute National Institutes of Health Stroke Scale was available for 89% of patients (375/421). Stroke severity was stratified as mild-moderate (National Institutes of Health Stroke Scale, 0-15) and severe (National Institutes of Health Stroke Scale ≥16; Figure 2 ). Overall, 92.5% of survivors had mild-moderate stroke (347/375), of whom 31.4% (109/347) had AF. In survivors, AF was associated with substantially greater 2-year costs in those with mild-moderate stroke (median, $45 140 versus $20 927; P<0.001), but no difference was observed in severe stroke (n=28; $118 704 versus $151 714; P=0.7; Figure 2) .
No relationship was observed between stroke severity and age (categorized as ≤60, 61-70, 71-80, and >80 years). Overall median costs were greater in AF-stroke in all age categories, but the difference was significant only in the 61-to 70-year subgroup (P=0.02; Figure I in the online-only Data Supplement). Our results were unchanged when the analysis 
Discussion
In our population-based study, the total cost of stroke in 568 patients was almost $34 000 000 in the first 2 years. AF-associated stroke contributed disproportionately to this cost burden. Although AF-stroke comprised 31% of the cohort, it accounted for 40% of the overall costs and 45% of nursing-home costs, with a 2-fold increase in median total costs compared with stroke without AF, mainly driven by higher acute hospitalization and nursing-home resource use and costs in patients who survived ≥90 days. Although greater age and comorbidity may contribute to greater cost of stroke in patients with AF, we observed a similar pattern of higher AF-associated costs across all age categories. AF is a modifiable, readily detected risk factor before stroke onset and many AF-associated strokes are preventable with anticoagulation therapy. Potential savings may be made by decreasing stroke risk by identifying and treating patients with AF, combined with avoidance of the disproportionately large costs which we have identified.
Increased costs relating to general practitioner visits and a trend toward greater community healthcare costs were also observed in AF-stroke although these accounted for a small proportion of overall costs. Our findings were unchanged when our analyses were restricted to patients with ischemic stroke or first-ever stroke, indicating that they are unlikely to be because of higher frequency of anticoagulant-related hemorrhage or recurrent stroke in patients with AF, which are associated with worse outcomes.
It is likely that the total cost associated with AF-stroke has been underestimated in previous studies. [12] [13] [14] [15] One study from Germany reported that higher hospital costs were associated with AF-stroke but included only selected hospital-admitted, nonaphasic patients surviving without severe disability at 1 year to provide follow-up interviews. 12 An analysis from the Swedish Riks-Stroke hospital registry also reported greater acute hospital costs with AF-stroke. 13 Other studies have reported AF-stroke costs as subgroups of cardioembolic stroke or all AF-related costs. 14, 15 Although providing valuable information, these studies have excluded patients with stroke and paroxysmal AF, or those with recurrent stroke (which may account for up to one fifth of all AF-stroke), and costs unrelated to acute hospitalization were not described. Systematic reviews have highlighted the need for national cost of illness estimates specific to AF-stroke. 22, 23 By comparison, our population-based study applied rigorous methods to achieve near-complete ascertainment according to recommended gold-standard criteria. 17 We included hospital-admitted patients and patients treated in the community with first-ever and recurrent stroke events and all pathological stroke types, with high follow-up rates at 2 years. In contrast to previous studies, we included patients with AF before stroke onset, new AF detected at stroke onset, and paroxysmal AF detected after stroke, leading to higher rates of AF in our cohort than previously described (31% compared with 19%-24% in earlier studies). 12, 13 We included patients with severe stroke and early fatality in our primary analysis and performed sensitivity analyses to ensure our findings were robust in clinically relevant subgroups.
Our inclusion of acute hospital, nursing-home, community healthcare, and indirect costs increases the likelihood that our cost estimate is likely to be a more accurate approximation of the total cost of AF-stroke compared with previous studies. We found substantially higher costs than previously describedthe mean 2-year cost in our study was €56 000 ($76 720) compared with €11 799 ($16 125; 1-year, direct costs) and €10 192 ($13 963; 3-year direct hospital costs) in Germany and Sweden. 12, 13 A recently published retrospective study estimated 2-year direct costs of up to €29 700 ($40 689). 24 However, cost comparisons across studies must be interpreted with caution because of differing methods and variability in costs compared with time and in different healthcare systems.
We acknowledge some limitations. The distribution of the cost data did not allow multivariable modeling to investigate the influence of potential confounding variables on the AF-cost relationship. On stratified analyses by fatality, age, and stroke severity, no clear influence of age or severity was detected. We cannot exclude the possibility that undetected residual confounding by age, severity, or other factors may partially explain our findings. We were unable to quantify some intangible costs, such as those associated with loss of quality of life to patients and cost of provision of informal caregiving by family members, who may be of working age, leading to underestimation of indirect caregiving costs. We assumed that some care patterns remained constant for the 2-year follow-up period (eg, continued prescription medication). Our findings are internally valid for the North Dublin population. However, their applicability to other populations with differing demographic characteristics, healthcare systems, or cost structures (external validity) should be interpreted with caution. Our study may have been underpowered to detect cost differences within some subgroups.
The World Health Organisation has emphasized the growing societal burden of noncommunicable diseases associated with lifestyle changes and improved life expectancy of global populations. 25 Guidelines and expert groups have recommended targeted health policy measures to respond to the growing prevalence of AF, such as national registries, populationwide screening programs, and AF clinics. 26, 27 Health system reimbursement decisions based on cost-effectiveness analyses of new oral anticoagulants are also critically dependent on underlying assumptions of the cost of stroke consequent to AF. 8, 9 For these reasons, accurate cost data are essential to inform policy decisions relating to the allocation of finite healthcare resources to prevent AF-stroke reliably. Our study provides more comprehensive data specific to AF-stroke than has previously been available. Further population-based cost studies are needed to confirm our findings in different healthcare systems.
SUPPLEMENTAL MATERIAL
Acute hospital, community, and indirect costs of stroke associated with atrial fibrillation -a population-based study Supplemental Methods:
Definitions:
Stroke was defined according to the WHO definition. The qualifying event was coded as first-ever stroke if no history of clinical stroke was present and as recurrent stroke if a history of clinical stroke existed prior to study onset. Ischaemic stroke was defined in the presence of an appropriate clinical syndrome, with evidence of cerebral infarction on brain magnetic resonance imaging (MRI) or computerised tomography (CT), or normal neuro-imaging with absence of brain haemorrhage, or pathological evidence of recent cerebral infarction at autopsy. Primary intracerebral haemorrhage (ICH) was verified by evidence of acute intraparenchymal haematoma on brain imaging or autopsy, and subarachnoid haemorrhage (SAH) as an appropriate clinical syndrome, with supportive brain imaging, cerebrospinal fluid, or pathological data. If neither brain imaging nor pathological examination were performed, the pathological subtype was coded as 'Unknown'. Stroke of unknown type was classified as ischaemic for comparison of pathological types. Disability was assessed using the modified Rankin score (mRS) within 72 hours and at 90 days, 1 and 2 years conducted by a trained research staff member using a standard algorithm. Acute stroke severity (<72 hours) was assessed by certified raters using the National Institutes of Health Stroke Scale (NIHSS).
Ascertainment:
Following a 10-week pilot study to refine procedures, individuals with stroke and TIA occurring over a one-year period (1/12/2005-30/11/2006) were identified. Ascertainment was continued for a further 3 months to identify eligible cases who delayed seeking medical attention. As per recommended criteria for stroke incidence studies, multiple overlapping sources, combining 'hot' and 'cold' pursuit, were used. For community ascertainment, 180/190 (94%) of North Dublin general practitioners and 17 of 18 (95%) nursing homes participated. All GPs and nursing homes were contacted every two weeks, with physician verification of community-treated patients in the clinic or at their homes. Community-treated patients with TIA and minor stroke were ascertained through a 5-day rapid access clinic. Patients with suspected stroke who died were ascertained by review of death certificates and pathology or coroner's records. All suspected TIA patients were assessed in-person and followed to detect minor stroke and new stroke after TIA. Patients with TIA, those in whom the diagnosis of stroke was unclear, and those with possible recurrent stroke were reviewed in-person by a study physician and eligibility for study inclusion agreed by consensus. For hospital ascertainment, daily checking of all emergency room and elective admissions, consultation requests, and admissions to specialist wards and intensive care units was performed. Staff at geriatric, neurology, vascular surgery, and ophthalmology outpatient clinics were regularly contacted to encourage referral of eligible patients. Patients with suspected stroke who died were ascertained by review of death certificates and pathology or coroner's records. Results for brain and neurovascular imaging in all radiology units serving the population were reviewed twice weekly, with in-person verification of patients with suspected stroke/TIA. All suspected TIA patients were assessed and followed prospectively to detect minor stroke and new stroke after TIA. Patients with TIA, those in whom the diagnosis of stroke was unclear, and those with possible recurrent stroke were reviewed in-person by a study physician and eligibility for study inclusion agreed by consensus. Individuals with stroke/TIA whose usual address was outside North Dublin city, but who were treated in North Dublin hospitals were excluded. Detailed demographic data are available from the 2006 Census, which was conducted during the study ascertainment period. The total population was 294,529 individuals, comprising 149,761 women (50.85%) and 144,698 men (49.15%), with 5.7% (16,638 individuals) aged 75 years or greater. The population is relatively stable, with low in-and outmigration. For identification of events in North Dublin residents who were treated outside the North Dublin area, clinicians involved in stroke care in other Dublin hospitals were directly contacted and the study publicised at regional and national meetings of general practitioners and stroke clinicians to encourage notification of eligible patients.
Cost estimates: Cost of Inpatient Care
The casemix approach to calculating costs is a 'top-down' approach which allocates total hospital costs across all discharges on the basis of casemix units rather than length of stay. Each stroke patient was assigned to a Diagnosis Related Group (DRG), where patients sharing common clinical attributes and patterns of resource use were grouped together. A casemix unit measures the complexity (quantified as resource use) of the DRG to which a patient has been assigned, relative to all other DRGs, and is adjusted to take into account the specific length of in-patient stay. 
Nursing Home Costs
Place of residence was assessed at each individual patient follow-up assessment (90-day, 1 year, and 2 year). Cost of residential nursing-home care following stroke was calculated for individual patients using a bottom-up approach. The unit costs for nursing home care were stratified by payer of nursing home bed provision (paid by the public health system or private funding) and by the level of dependency (90-day post-stroke modified Rankin Score categorized as 0-1, 2-3, 4-5) (Supplementary Table I) . 1 Patients transferred to nursing home care had nursing home length of stay calculated based on date of discharge or death. It was assumed that each surviving patient was resident in the nursing home for the period of time between follow-ups.
Other direct costs of non-hospital care:
A bottom-up approach was used to calculate the individual patient direct costs for time spent outside hospital (either post-hospital discharge or within the community in patients not admitted) within the 2-year post-stroke period. The cost of general practitioner community physician visits was calculated per individual, with adjustment for whether the patient was a nursing home resident and the degree of health system subvention by the government 'medical card' scheme). We estimated two stroke-related GP visits per annum, with adjustment for death and post-stroke hospitalisation within the follow-up period. (Supplementary Table II) The cost of outpatient visits to hospital stroke specialists, hospital-based anticoagulation clinics, and attendance at rapid access TIA clinics was estimated for the overall cohort from data using a representative sample of recorded outpatient visits by surviving study participants (48 patients, 11% of 90-day survivors, stratified by initial stroke severity [NIHSS] ). All outpatient visits occurred within the stateprovided hospital system. Costs were estimated based on hospital finance department data at one acute hospital $186(€136) per general outpatient clinic attendance, $212 (€155) per neurology specialist visit). Cost of attendance at a hospital anticoagulation clinic was estimated as $417.82 (€304.98) per annum by micro-costing the service (nurse, doctor, equipment and laboratory costs) in audit data presented at the Royal College of Surgeons of Ireland. 2 The cost of prescribed medicines for stroke treatment and prevention (ie. medication specifically related to the stroke event) was calculated using monthly ingredient cost per medication (including dispensing fees and/or markups) multiplied by number of months out-of-hospital. 1 We recorded medications prescribed pre-stroke and at discharge (or at time of death) for each stroke patient. For this analysis, we included specific stroke-related medication categories including antithrombotic medications (aspirin, clopidogrel, dipyridamole), lipid lowering medications (statins, others), and anti-hypertensives (diuretic, beta-blockers, calcium channel blockers, ACE inhibitor, ARB antagonist, alpha blocker). Prescribing of new post-stroke medications was calculated together with the number of months during which out-of-hospital prescriptions were required in the 2-year follow-up period for each individual stroke patient. It was assumed that all post-stroke medications were prescribed continually in the follow-up period with no changes. Patients presenting with a second or recurrent stroke (who may already have been prescribed secondary stroke prevention medications) had costs calculated based on the discharge medications, from the recurrent stroke. It is worth noting that the data was collected prior to the publication of trials regarding the newer anticoagulant drugs and their subsequent licensing for use in stroke prevention with AF. Utilisation of supportive community services (such as home help, meals on wheels, and formal home healthcare support for assistance in personal activities of daily living) was assessed at NDPSS follow-up at 90-days, 1 and 2 years post-stroke. The reported use of these services was stratified based on post-stroke disability level (Supplementary Table III) The costs of aids, appliances, and home modifications required by post-stroke patients were calculated using unit cost data based on 2007 prices, and applied to individual patients based on utilization on 90-day follow up, stratified by disability level (Supplementary Table IV). 1 Lost productivity costs due to morbidity To partially estimate indirect costs of stroke, we estimated loss of productivity due to stroke during hospital admission. We adopted the 'human capital' approach, calculating the amount of earnings in employment lost due to illness. Employment data on all patients (including homemakers) were recorded at the time of stroke onset in NDPSS. Using the length of hospital stay, we estimated time lost from work as one day lost for every day spent in hospital. Unit costs of productivity lost were estimated as follows: the Irish national median wage where stroke patient was engaged in paid work ($22 
